Vision-Threatening Infantile Hemangioma of the Upper Eyelid
A 10-week-old girl is brought by her parents because of a red, raised lesion on the left upper eyelid that appeared at 2 weeks of age and has grown rapidly over the past 3 weeks. It measures 1.2 cm and causes mechanical ptosis, partially covering the visual axis when she is tired. She is otherwise healthy, born at term, with normal growth and no stridor or respiratory symptoms. Physical examination shows a bright red, compressible plaque with a modest deep component; there are no other hemangiomas. The parents are anxious about vision and about starting a beta-blocker. They ask whether treatment can wait, what tests are needed before propranolol, and what alternatives exist.
1. Justify the urgency of treatment and outline the pre-treatment evaluation for oral propranolol in this infant.
Read the worked answer
Urgency: This hemangioma is vision-threatening because it causes mechanical ptosis and can induce amblyopia, astigmatism, or strabismus. The proliferative phase peaks around 3–6 months, so waiting risks irreversible visual impairment. Treatment should start within days, not weeks.
Pre-treatment evaluation:
- History and physical examination, including cardiac and respiratory assessment.
- Baseline heart rate, blood pressure, and oxygen saturation.
- ECG is reasonable to exclude heart block or arrhythmia. Echocardiography is indicated if there is a murmur, cardiac history, or signs of heart failure; it is not routine for all infants.
- Blood glucose is checked at baseline in some protocols, especially in small or poor-feeding infants.
- If the hemangioma were segmental, large, or associated with stridor, evaluate for PHACE syndrome and airway hemangioma. This lesion is localized, so routine MRI is not needed.
- Confirm no contraindications: asthma, bronchospasm, heart block, or cardiogenic shock.
Counseling: Explain that propranolol is the first-line treatment and that the benefits of preventing blindness outweigh the small risks. Obtain informed consent.
2. Describe the initiation, titration, and monitoring of propranolol, including common adverse effects.
Read the worked answer
Initiation: Start propranolol at 1 mg/kg/day divided into two or three doses. Many protocols use twice-daily dosing. Give with feeds to reduce hypoglycemia risk.
Titration: Increase to 2 mg/kg/day after 1 week if tolerated, and up to 3 mg/kg/day if needed. The target is usually 2–3 mg/kg/day. Reassess the hemangioma every 4 weeks during proliferation; treatment is often continued until 12–18 months of age.
Monitoring:
- Check heart rate, blood pressure, and glucose 1–2 hours after the first dose and after each dose increase.
- Parents should feed regularly and avoid prolonged fasting.
- Monitor for sleep disturbance, diarrhea, cold extremities, bronchospasm, and hypoglycemia (jitteriness, sweating, lethargy).
- If the infant becomes ill with vomiting or poor feeding, hold the dose and seek medical advice.
Contraindications: asthma, bronchospasm, heart block, and decompensated heart failure. Use caution in infants with PHACE syndrome and cerebrovascular anomalies; coordinate with neurology.
Expected response: Color and size improve within weeks. Residual fibrofatty tissue may persist after involution.
3. If propranolol is contraindicated or refused, what alternatives would you consider, and how would you monitor vision?
Read the worked answer
Alternatives:
- Topical timolol gel 0.5% twice daily can be used for superficial eyelid hemangiomas, but efficacy is lower for deep or rapidly growing lesions. Monitor for systemic absorption and bradycardia.
- Oral corticosteroids (for example, prednisolone 2–3 mg/kg/day) can slow proliferation but have significant adverse effects, including growth suppression, hypertension, and immunosuppression. They are a short-term option if beta-blockers are contraindicated.
- Pulsed dye laser can treat superficial redness and ulceration but does not penetrate deep components.
- Surgical excision is rarely first-line but may be considered for a well-localized lesion causing severe ptosis after the proliferative phase.
Vision monitoring:
- Urgent pediatric ophthalmology assessment for visual acuity, refractive error, and amblyopia risk.
- Treat amblyopia with patching or glasses as directed.
- Follow up every 4–8 weeks during infancy, then as needed.
Counseling: Even with treatment, residual skin changes and ptosis can occur. Early intervention gives the best visual outcome.